1.61
+12.59%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About MetaVia
From its filings with the US Securities and Exchange Commission
MetaVia is based in Cambridge, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker MTVA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $13.0m. At that date it held total assets of $11.1m and shareholders' equity of $5.3m.
We are a clinical-stage biotechnology company focused primarily on developing novel pharmaceuticals to treat cardiometabolic diseases. We have two programs focused primarily on the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and obesity.
Quoted from its 10-K, filed 26 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 5 Aug 2016
- Employees
- 9
- Website
- neurobopharma.com ↗
- Head office
- 545 CONCORD AVENUE, CAMBRIDGE, MA, 02138
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Andrew KovenIndependent Chairman of the Board$113,850
- Mr. Hyung KimPresident, Chief Executive Officer, Director, since 2021$716,404
- Mr. Marshall WoodworthChief Financial Officer$774,699
- Mr. Mark GlickmanIndependent Director$74,850
- Mr. Jason GrovesIndependent Director$64,850
- Mr. Michael SalsburyIndependent Director$71,850
- Mr. D. Gordon StricklandIndependent Director$83,850
- Dr. James TursiIndependent Director$64,850
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 34
- Environment
- 36
- Social
- 43
- Governance
- 24
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- NeuroBo Pharmaceuticals focuses on treating neurodegenerative disorders with NB-01 for PDN and NB-02 for Alzheimer's.
- The company addresses unmet needs in Painful Diabetic Neuropathy and Alzheimer's disease with its product candidates.
- Gemcabene targets dyslipidemia with orphan indications like HoFH and SHTG for cardiovascular risk reduction.
Weaknesses
- NeuroBo Pharmaceuticals has only 9 employees, which may limit its operational capacity.
- The company's clinical-stage focus requires significant capital investment for development.
- Its product candidates are still in development without approved treatments yet.
Opportunities
- The growing market for neurodegenerative disorder treatments offers expansion potential.
- NB-02's focus on Alzheimer's and tauopathies aligns with increasing global aging populations.
- Gemcabene's orphan indications in HoFH and SHTG present niche market opportunities.
Threats
- NeuroBo Pharmaceuticals faces competition from established biotech firms in neurodegenerative treatments.
- Regulatory hurdles could delay the approval of NB-01 and NB-02 for PDN and Alzheimer's.
- The clinical-stage nature of its products poses high development risks and potential failure rates.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.